[{"id":"5fb2a2a3-8028-4771-9421-4a4933245c34","acronym":"FIORELLA","url":"https://clinicaltrials.gov/study/NCT03495960","created_at":"2021-01-18T17:12:50.063Z","updated_at":"2025-02-25T17:29:39.803Z","phase":"Phase 2","brief_title":"Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System","source_id_and_acronym":"NCT03495960 - FIORELLA","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • temozolomide • Matulane (procarbazine hydrochloride)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 06/15/2019","start_date":" 06/15/2019","primary_txt":" Primary completion: 12/12/2024","primary_completion_date":" 12/12/2024","study_txt":" Completion: 12/12/2024","study_completion_date":" 12/12/2024","last_update_posted":"2025-01-30"},{"id":"230f4945-9e53-43b8-a919-d415d3413b87","acronym":"","url":"https://clinicaltrials.gov/study/NCT00887146","created_at":"2021-01-18T03:23:40.025Z","updated_at":"2024-07-02T16:35:01.239Z","phase":"Phase 3","brief_title":"Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma","source_id_and_acronym":"NCT00887146","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" IDH1 • IDH2","pipe":"","alterations":" ","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vincristine • Matulane (procarbazine hydrochloride)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-05-23"},{"id":"6358176d-fc44-4d02-9e47-56116f950879","acronym":"","url":"https://clinicaltrials.gov/study/NCT00574496","created_at":"2021-01-18T02:05:52.845Z","updated_at":"2024-07-02T16:35:35.650Z","phase":"Phase 2","brief_title":"Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT00574496","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD20 • HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["CD20 • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • cyclophosphamide • ifosfamide • vincristine • vinorelbine tartrate • prednisone • melphalan • fludarabine IV • Matulane (procarbazine hydrochloride) • cyclosporine • Mustargen (mechlorethamine)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/13/2007","start_date":" 11/13/2007","primary_txt":" Primary completion: 08/02/2022","primary_completion_date":" 08/02/2022","study_txt":" Completion: 08/02/2022","study_completion_date":" 08/02/2022","last_update_posted":"2023-09-27"},{"id":"4f03f71b-4bd9-45f1-980c-fad65248deab","acronym":"","url":"https://clinicaltrials.gov/study/NCT01775475","created_at":"2021-01-29T07:04:14.975Z","updated_at":"2024-07-02T16:36:02.736Z","phase":"Phase 2","brief_title":"Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01775475","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • lomustine • Matulane (procarbazine hydrochloride) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 09/15/2016","start_date":" 09/15/2016","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 07/15/2021","study_completion_date":" 07/15/2021","last_update_posted":"2022-10-10"},{"id":"712abef4-ee9f-449b-a706-9e273acea522","acronym":"","url":"https://clinicaltrials.gov/study/NCT00822120","created_at":"2021-01-18T03:07:31.140Z","updated_at":"2024-07-02T16:36:05.303Z","phase":"Phase 2","brief_title":"S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma","source_id_and_acronym":"NCT00822120","lead_sponsor":"Southwest Oncology Group","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • dacarbazine • Matulane (procarbazine hydrochloride) • bleomycin • vinblastine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 371","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 04/30/2016","primary_completion_date":" 04/30/2016","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2022-08-18"},{"id":"d4393a9c-c069-473a-ab37-f7c924576c0d","acronym":"BRAPP2","url":"https://clinicaltrials.gov/study/NCT02298283","created_at":"2021-01-18T10:50:17.525Z","updated_at":"2024-07-02T16:36:27.463Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD","source_id_and_acronym":"NCT02298283 - BRAPP2","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • vincristine • prednisone • Matulane (procarbazine hydrochloride) • bleomycin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 07/09/2020","primary_completion_date":" 07/09/2020","study_txt":" Completion: 07/09/2020","study_completion_date":" 07/09/2020","last_update_posted":"2021-07-26"},{"id":"344a185c-4d14-4622-97e3-9f7082b8a174","acronym":"","url":"https://clinicaltrials.gov/study/NCT01132807","created_at":"2021-01-29T07:00:47.583Z","updated_at":"2024-07-02T16:36:29.143Z","phase":"Phase 2","brief_title":"Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma","source_id_and_acronym":"NCT01132807","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • dacarbazine • Matulane (procarbazine hydrochloride) • bleomycin • vinblastine • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 164","initiation":"Initiation: 05/01/2010","start_date":" 05/01/2010","primary_txt":" Primary completion: 02/01/2016","primary_completion_date":" 02/01/2016","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2021-06-14"},{"id":"48bc3925-f5dd-46b4-b5d5-b7d989e551a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00151281","created_at":"2021-01-18T00:30:54.507Z","updated_at":"2024-07-02T16:37:09.373Z","phase":"Phase 2","brief_title":"Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma","source_id_and_acronym":"NCT00151281","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD20 • CCND1 • CD5 • MME • FCER2","pipe":"","alterations":" ","tags":["CD20 • CCND1 • CD5 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • etoposide IV • prednisone • thalidomide • Matulane (procarbazine hydrochloride)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 11/01/2004","start_date":" 11/01/2004","primary_txt":" Primary completion: 12/01/2009","primary_completion_date":" 12/01/2009","study_txt":" Completion: 04/07/2011","study_completion_date":" 04/07/2011","last_update_posted":"2018-06-28"}]